The board of directors of SSY Group Limited announced that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Mecobalamin Injection (1ml: 0.5mg). Mecobalamin Injection is mainly used in treatment of peripheral neuropathy and macrocytic anemia caused by vitamin B12 deficiency. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.78 HKD | +1.70% | -0.21% | -3.24% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.24% | 1.82B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
-3.40% | 157B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Announces Approval of Mecobalamin Injection by National Medical Products Administration of China